MED vs MKC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

MED

32.2
AI Score
VS
MKC Wins

MKC

48.7
AI Score

Investment Advisor Scores

MED

32score
Recommendation
SELL

MKC

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED MKC Winner
Revenue 224.48M 5.84B MKC
Net Income -22.73M 1.26B MKC
Gross Margin 69.1% 39.1% MED
Net Margin -10.1% 21.7% MKC
Operating Income -26.98M 720.90M MKC
ROE -12.6% 18.0% MKC
ROA -9.5% 7.6% MKC
Total Assets 239.76M 16.65B MKC
Cash 58.37M 331.10M MKC
Current Ratio 4.82 0.66 MED
Free Cash Flow 2.76M 467.60M MKC

Relative Price Performance (Last 90 Days)

MED 1M: +8.5% · 3M: +12.4% MKC 1M: +3.6% · 3M: -15.1%

Current Technical Phase

MED

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 57

RSI (14): 56.9 · Price: $12.86

MKC

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.4%), weak momentum, RSI 45

RSI (14): 44.8 · Price: $46.41

Fundamentals Snapshot

Metric MED MKC
Market Cap — —
Forward P/E -321.5 14.5
Trailing P/E — 8.4
Revenue (TTM) — —
Revenue Growth -0.2% 0.2%
Gross Margin 0.7% 0.4%
Operating Margin -0.1% 0.2%
EPS -3.70 5.56
Dividend Yield — 0.04%

Frequently Asked Questions

Based on our detailed analysis, MKC is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.